Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens
K. Rajender Reddy(Hospital of the University of Pennsylvania), Stephanie Noviello(Novartis (United States)), Kazuaki Chayama(RIKEN Center for Integrative Medical Sciences), Adrián Gadano(Hospital Italiano de Buenos Aires), Wayne Ghesquière(Island Health), Jeong Heo(National Cancer Center), Rong Yang(Guangzhou First People's Hospital), Paul J. Thuluvath(University of Maryland, Baltimore), Misti Linaberry(Bristol-Myers Squibb (United States)), Cheng‐Yuan Peng(China Medical University), Zhaohui Liu(Wuhan University of Technology), Eric Lawitz(The University of Texas at San Antonio Health Science Center), Stanislas Pol(Université Paris Cité), Maurizia Rossana Brunetto(University of Pisa), Simone I. Strasser(University of Padua), Fiona McPhee(Bristol-Myers Squibb (United States)), Marcelo Silva(Hospital Universitario Austral), Hiromitsu Kumada(Toranomon Hospital), Joji Toyota(Sapporo Kosei General Hospital), James Levin(Cidara Therapeutics (United States)), Guido Gerken
Cited by 24
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k